A quantitative DCE-MRI-based multi-omics model for predicting immune microenvironment characteristics and prognosis of triple-negative breast cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600127165

Enrollment

Unknown

Registered

2026-06-25

Start date

2026-06-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

High FAP+ Group and Low FAP+ Group:None

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Postoperative pathological diagnosis of invasive breast carcinoma of no special type (NST); 2. Diagnosis of triple-negative breast cancer (TNBC) based on immunohistochemical marker results; 3. No prior history of breast cancer; 4. No prior history of breast radiation; 5. Complete clinicopathological data available for the patient.

Exclusion criteria

Exclusion criteria: 1. Patients initially diagnosed with bilateral breast cancer; 2. Patients with biopsy-proven TNBC who received neoadjuvant therapy; 3. Patients lost to follow-up.

Design outcomes

Primary

Measure	Time frame
FAP+ cancer-associated fibroblasts abundance (high vs low expression);Tumor-infiltrating lymphocytes (TILs) proportion;Overall survival (OS);	—

Countries

China

Contacts

Public ContactWang Dengbin

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

wangdengbin@xinhuamed.com.cn+86 21 25077030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026